Drugs / PLB-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07304128 | Feb 2026 → Jun 2027 expected | neoplasm | Primelink BioTherapeitics(ShenZhen) Limited | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLB-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07304128 ↗ |